This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Corsten, M. F. Articles by Reutelingsperger, C. P.M. Search for Related Content PubMed PubMed Citation Articles by Corsten, M. F. Articles by Reutelingsperger, C. P.M. Related Collections Tumor Biology Tumor Biology: Model Organisms and Imaging Cancer Immunology: Adaptive Immunity

Counting Heads in the War against Cancer: Defining the Role of Annexin A5 Imaging in Cancer Treatment and Surveillance

Departments of ¹ Cardiology and ² Biochemistry, Cardiovascular Research Institute Maastricht, University Maastricht, MD Maastricht, the Netherlands and ³ Department of Cardiology, University of California, Irvine, School of Medicine, UCI Medical Center, Orange, California

Requests for reprints: Chris P.M. Reutelingsperger, Department of Biochemistry, Cardiovascular Research Institute Maastricht, P. Debyelaan 25, 6229 AD, Maastricht, the Netherlands. Phone: 31-43-387-5093; Fax: 31-43-387-5104; E-mail: C.Reutelingsperger{at}bioch.unimaas.nl.

The unveiling of the heterogeneous nature of cell death modes has compromised the long-lived consensus that cancer treatment typically kills cancer cells through apoptosis. Moreover, it implies that measures of apoptosis may be misleading indicators of treatment efficacy. Simultaneously, it has become clear that phosphatidylserine exposition, traditionally considered a hallmark of apoptosis, is also associated with most other cell death programs, rendering phosphatidylserine an attractive target for overall cell death imaging. Annexin A5 binds with strong affinity to phosphatidylserine and hence offers an interesting opportunity for visualization of aggregate cell death, thus providing a fit benchmark for in vivo monitoring of anticancer treatment. This might be of significant value for pharmacologic therapy development as well as clinical monitoring of treatment success. (Cancer Res 2006; 66(3): 1255-60)

This article has been cited by other articles:

				R. I. Sharma and T. A.D. Smith Colorectal Tumor Cells Treated with 5-FU, Oxaliplatin, Irinotecan, and Cetuximab Exhibit Changes in 18F-FDG Incorporation Corresponding to Hexokinase Activity and Glucose Transport J. Nucl. Med., August 1, 2008; 49(8): 1386 - 1394. [Abstract] [Full Text] [PDF]

				M. Kartachova, N. van Zandwijk, S. Burgers, H. van Tinteren, M. Verheij, and R. A. Valdes Olmos Prognostic Significance of 99mTc Hynic-rh-Annexin V Scintigraphy During Platinum-Based Chemotherapy in Advanced Lung Cancer J. Clin. Oncol., June 20, 2007; 25(18): 2534 - 2539. [Abstract] [Full Text] [PDF]

				K. M. Brindle Detecting Early Tumor Responses to Therapy Using Magnetic Resonance Imaging and Spectroscopy Am. Assoc. Cancer Res. Educ. Book, April 14, 2007; 2007(1): 85 - 90. [Full Text] [PDF]

				S. Rottey, G. Slegers, S. Van Belle, I. Goethals, and C. Van de Wiele Sequential 99mTc-Hydrazinonicotinamide-Annexin V Imaging for Predicting Response to Chemotherapy J. Nucl. Med., November 1, 2006; 47(11): 1813 - 1818. [Abstract] [Full Text] [PDF]

				W. S. El-Deiry The Promise of Optical Technologies for Measuring Tumor Response in Cancer Therapy Trials Am. Assoc. Cancer Res. Educ. Book, April 1, 2006; 2006(1): 143 - 146. [Full Text] [PDF]